BetterLife Pharma Inc. (BETR.CN)
| Previous Close | 0.0800 |
| Open | 0.1000 |
| Bid | 0.0800 x N/A |
| Ask | 0.1050 x N/A |
| Day's Range | 0.1000 - 0.1000 |
| 52 Week Range | 0.0800 - 0.3650 |
| Volume | |
| Avg. Volume | 47,661 |
| Market Cap | 8.54M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1610 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr. Ahmad Doroudian, Chief Executive Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 1st Annual Mental Health Conference being held on June 27th, 2022 in New York Cit
- GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract submitted on the anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for poster presentation at the upcoming FENS Forum, being held July 9-13 in Paris,
- GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for presentation at the upcoming Canadian Association for Neuroscience
